EGFR and lung carcinoma: Updated recommendations from the College of American Pathologists, International Association for the Study of Lung Cancer, Association for Molecular Pathology (CAP/IASCL/AMP), and European Society of Medical Oncology (ESMO) have strengthened the 2013 guidelines and suggest genomic testing for EGFR, ALK, and ROS1 for all advanced NSCLC, regardless of patients’ characteristics [7].